Today’s Watchlist: Get Ainos, Inc. (NASDAQ: AIMD) on Your Screen Early This Morning - Or You Could Miss It

Breaking Now: Immediately add Ainos, Inc. (NASDAQ: AIMD) to Your Watchlist This Morning! Don’t Miss Out on This One! Take a Look at (AIMD) Now or You Could Miss It! High Insider Confidence: With over 81% insider ownership, Ainos, Inc. (NASDAQ: AIMD)’s leadership strongly believes in the company's growth and future potential. Limited Public Float: Less than 1.5M shares available, making Ainos, Inc. (NASDAQ: AIMD) one company to keep a close eye on.  Innovative Product Pipeline: VELDONA®, a low-dose oral interferon with FDA orphan status, is set to address rare, difficult-to-treat conditions. AI-Driven Healthcare Solutions: Ainos, Inc. (NASDAQ: AIMD)’s AI-powered point-of-care testing and AI Nose technology put it at the forefront of healthcare innovation. FDA-Backed Regulatory Advantages: VELDONA® benefits from fast-tracked approval and market exclusivity due to its FDA orphan status. Don’t Miss Ainos, Inc. (NASDAQ: AIMD)! Take 2 Minutes Now to Connect with Us on all of Our No-Cost Platforms! (See instructions below) October 2, 2024 Dear Reader, This just came across my desk and you need to have it on your watchlist this morning.  Immediately start your research on Ainos, Inc. (NASDAQ: AIMD).  Ainos, Inc. (NASDAQ: AIMD), headquartered in San Diego, is a cutting-edge healthcare company making strides in the world of AI-powered solutions.  With a limited float of fewer than 1.5M shares and over 81% insider ownership, it’s clear the people closest to the company believe in its potential.  This combination of next-gen technology and strong internal backing positions Ainos as a standout in the healthcare sector. At the heart of Ainos, Inc. (NASDAQ: AIMD)’s progress is their revolutionary product, VELDONA®, a low-dose oral interferon therapy that’s already earned orphan designation from the U.S. FDA. This recognition highlights VELDONA®’s potential to address rare and difficult-to-treat conditions. Currently, Ainos is spearheading a groundbreaking clinical trial at National Taiwan University Hospital.  The study is focused on using VELDONA® to treat HIV-related oral warts, a common and debilitating complication among HIV-positive patients. This clinical trial is a major milestone for the company.  It not only underscores the potential of VELDONA® as a therapeutic option for HIV-positive individuals but also fast-tracks the dr-ug's path to commercialization, thanks to its orphan designation.  The trial will assess the safety and efficacy of VELDONA® in combination with standard antiretroviral therapy, with results expected to make waves in the medical community. With over 39M people living with HIV globally, this is a significant area of unmet need.  The FDA’s orphan status offers VELDONA® several regulatory advantages, including extended market exclusivity and fast-tracked approval processes, giving Ainos, Inc. (NASDAQ: AIMD) a competitive edge in bringing this much-needed therapy to market. Ainos, Inc. (NASDAQ: AIMD) is not stopping there.  Their AI-powered point-of-care testing (POCT) platform, driven by their proprietary AI Nose technology, aims to further empower individuals with accessible, real-time healthcare solutions.  This diversified portfolio, which combines AI with healthcare, positions Ainos at the forefront of the next wave of health-tech innovation. With fewer than 1.5M shares available and insider confidence at a remarkable 81%, the time to take a look at Ainos, Inc. (NASDAQ: AIMD) is now. Ainos, Inc. (NASDAQ: AIMD) is a company actively advancing innovative healthcare solutions with significant market potential.  Their recent clinical trial initiation represents not just a step forward, but a leap toward addressing global health challenges through AI and novel therapies. Make sure Ainos, Inc. (NASDAQ: AIMD) is on your watchlist today. In the meantime,  I’m urging you to connect with us on all of our no-cost platforms so you can receive our reports up to 10X faster than email alone. If you haven't already, please take a moment to set up these platforms now: SMS: To make sure you’re signed up for our no-cost SMS Alerts, which are up to 10X faster than email, click here. Telegram Channel: Click now to join our no-cost Telegram Channel for real-time updates. WhatsApp: Or if you prefer WhatsApp, click here to join our real-time Market Chatter. All three of these should take less than 3 minutes to connect but could give you a massive advantage in the market.  Make no mistake –  Ainos, Inc. (NASDAQ: AIMD) needs to be #1 on your watchlist this morning (October 2, 2024) or you could miss it. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux (MarketCrux . com) is owned by Headline Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. MarketCrux full disclosure is to be read and fully understood before using MarketCrux website, or joining MarketCrux's email or text list. By viewing MarketCrux website and/or reading MarketCrux email or text newsletter you are agreeing to MarketCrux full disclosure which can be read at marketcrux.com/disclaimer We have not been compensated for October 2, 2024’s profile on (AIMD:US). We own zero shares of (AIMD:US).

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice